Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 4 other studies
9,341people in the A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events trial, from 2010
9,340of them with kidney disease, in this paper
The trial randomly assignedassigned by chance
liraglutide
placebo
Lowered new onset of persistent macroalbuminuria−26%
Lowered renal outcome−22%
randomisedthe abstract, start to end
… patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], …
… (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; …
← favours treatmentfavours comparator →
could be chanceRenal outcomeliraglutide vs placebo
HR 0.780.67–0.92
New onset of persistent macroalbuminurialiraglutide vs placebo
HR 0.740.60–0.91
GLP-1 receptor agonistsKidney outcomes
GLP-1 receptor agonists × kidney outcomeshelps?mixed
unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
1 / 7